These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 31745297

  • 1. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.
    Kumarasamy V, Ruiz A, Nambiar R, Witkiewicz AK, Knudsen ES.
    Oncogene; 2020 Feb; 39(9):1831-1845. PubMed ID: 31745297
    [Abstract] [Full Text] [Related]

  • 2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [Abstract] [Full Text] [Related]

  • 3. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.
    Salvador-Barbero B, Álvarez-Fernández M, Zapatero-Solana E, El Bakkali A, Menéndez MDC, López-Casas PP, Di Domenico T, Xie T, VanArsdale T, Shields DJ, Hidalgo M, Malumbres M.
    Cancer Cell; 2020 Mar 16; 37(3):340-353.e6. PubMed ID: 32109375
    [Abstract] [Full Text] [Related]

  • 4. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ, Zhuang ZN, Li H, Tian T, Lu YX, Fan XQ, Zhou HJ, Mo HY, Sheng H, Chiao PJ, Xu RH.
    Cancer Lett; 2016 Aug 28; 379(1):1-11. PubMed ID: 27233476
    [Abstract] [Full Text] [Related]

  • 5. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
    Willobee BA, Gaidarski AA, Dosch AR, Castellanos JA, Dai X, Mehra S, Messaggio F, Srinivasan S, VanSaun MN, Nagathihalli NS, Merchant NB.
    Mol Cancer Ther; 2021 Jul 28; 20(7):1246-1256. PubMed ID: 34001634
    [Abstract] [Full Text] [Related]

  • 6. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D.
    Mol Cancer Ther; 2020 Aug 28; 19(8):1623-1635. PubMed ID: 32430484
    [Abstract] [Full Text] [Related]

  • 7. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
    Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES.
    Oncotarget; 2015 Jun 30; 6(18):15788-801. PubMed ID: 26158861
    [Abstract] [Full Text] [Related]

  • 8. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
    Heilmann AM, Perera RM, Ecker V, Nicolay BN, Bardeesy N, Benes CH, Dyson NJ.
    Cancer Res; 2014 Jul 15; 74(14):3947-58. PubMed ID: 24986516
    [Abstract] [Full Text] [Related]

  • 9. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F, Pajic M, Shi W, Kalimutho M, Miranda M, Nagrial AM, Chou A, Biankin AV, Grimmond SM, Australian Pancreatic Cancer Genome Initiative, Brown MP, Khanna KK.
    Clin Cancer Res; 2014 Jun 15; 20(12):3187-97. PubMed ID: 24838526
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
    Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, Shaffer AL, Louie T, Chen I, Randolph S, Hahn WC, Staudt LM, Niesvizky R, Moore MA, Chen-Kiang S.
    Blood; 2012 Aug 02; 120(5):1095-106. PubMed ID: 22718837
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G, Zhao J, Qin C, Zhang Z, Lin Y, Su Z.
    Cancer Lett; 2017 Jan 28; 385():65-74. PubMed ID: 27840243
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L, Yao J, Li W, Zhang C.
    Oncol Res; 2018 Jul 05; 26(6):827-835. PubMed ID: 28477403
    [Abstract] [Full Text] [Related]

  • 17. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.
    Franco J, Witkiewicz AK, Knudsen ES.
    Oncotarget; 2014 Aug 15; 5(15):6512-25. PubMed ID: 25156567
    [Abstract] [Full Text] [Related]

  • 18. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N, Milioli HH, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Halilovic E, Segara D, Parker A, Haupt S, Haupt Y, Tilley WD, Swarbrick A, Caldon CE, Lim E.
    Breast Cancer Res; 2020 Aug 12; 22(1):87. PubMed ID: 32787886
    [Abstract] [Full Text] [Related]

  • 19. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H, Gao W, Li X, Yu L, Luo D, Liu Y, Yu X.
    Pancreatology; 2021 Apr 12; 21(3):589-598. PubMed ID: 33579599
    [Abstract] [Full Text] [Related]

  • 20. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ, Xu RH.
    J Pineal Res; 2016 Jan 12; 60(1):27-38. PubMed ID: 26445000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.